Previous Pause Next
Home >> News Center >>
Clinical Trials
Pfizer Negotiates Global Rights to GlycoMimetics’ Phase II Sickle Cell Crisis Drug PDF Print E-mail
Thursday, 13 October 2011 00:50

Pfizer negotiated exclusive worldwide rights to develop GlycoMimetics’ pan-selectin antagonist GMI-1070, in a deal which could be worth $340 million to GlycoMimetics in up-front and development, regulatory, and commercialization milestones, plus additional sale royalties. 

Intellikine Initiates Phase I Study of Targeted Cancer Therapeutic INK1117 PDF Print E-mail
Wednesday, 12 October 2011 01:27

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies. INK1117, a selective, orally available, small molecule inhibitor of the PI3Kalpha isoform has demonstrated impressive efficacy in several PI3Kalpha mutant-specific preclinical tumor models.

Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients PDF Print E-mail
Tuesday, 11 October 2011 17:41
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients.
Boston Therapeutics to Start Clinical Trial in Type 2 Diabetes PDF Print E-mail
Tuesday, 11 October 2011 17:35

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

Targacept Initiates a Phase 2b Study of AZD3480 in Alzheimer’s Disease PDF Print E-mail
Monday, 10 October 2011 05:28

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer’s disease.

Millennium Provides Update On SNDA For VELCADE In Relapsed Follicular Lymphoma PDF Print E-mail
Saturday, 08 October 2011 01:21

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) announced that it is withdrawing the supplemental new drug application (sNDA) for the use of VELCADE® (bortezomib) for Injection in combination with rituximab in patients with relapsed follicular lymphoma.

BioCancell to Commence Enrollment of Phase IIb Pancreatic Cancer Clinical Trial PDF Print E-mail
Friday, 07 October 2011 01:29

Tikcro Technologies Ltd. (Pink Sheets: TIKRF)(“Tikcro”) announced today that BioCancell, a clinical stage biotechnology company focused on developing targeted cancer therapies for solid cancer tumors, in which Tikcro holds approximately 26% on a fully diluted basis, has commenced enrollment of its Phase IIb pancreatic cancer clinical trial with a first treatment of the first patient.

New Data Show Favorable Outcomes On Measures Of Quality Of Life And Toxicity For Prostate Radiosurgery Using Varian And Calypso Technology PDF Print E-mail
Thursday, 06 October 2011 04:36

Early results from a prospective Phase II trial presented at the American Society of Radiation Oncology 53rd annual meeting show that patients with low-risk prostate cancer who were treated with radiosurgery using treatment technologies from Varian Medical Systems (NYSE: VAR) and Calypso Medical Systems had favorable health-related quality of life scores and minimal toxicities.

Journal Of Clinical Oncology Publishes Phase 2 Clinical Trial Results Of KRX-0401 (Perifosine) Plus Capecitabine In Patients With Metastatic Colorectal Cancer PDF Print E-mail
Thursday, 06 October 2011 04:33
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that a manuscript entitled "Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine as Second- or Third-Line Therapy in Patients with Metastatic Colorectal Cancer" reporting Phase 2 activity of KRX-0401 (perifosine) in the treatment of patients with refractory, advanced colorectal cancer (mCRC), was selected for publication in the October 3, 2011 online edition of the Journal of Clinical Oncology (JCO).
Phase I/II Study Evaluating ABRAXANE® Clinical Potential in Patients with Advanced Pacreatic Cancer Published in the Journal of Clinical Oncology Online PDF Print E-mail
Thursday, 06 October 2011 04:27

Celgene International Sàrl (Nasdaq:CELG) today announced that results from a clinical study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

Azelon Pharmaceuticals Secures $4.5 Million in Series A Financing to Support Phase 2 Study of Nasal Spray Teriparatide (PTH1-34) for the Treatment of Osteoporosis PDF Print E-mail
Wednesday, 12 October 2011 01:29

Azelon Pharmaceuticals, formerly Zelos Therapeutics, announced a restructuring of the company that includes additions to the management team.

Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302 PDF Print E-mail
Tuesday, 11 October 2011 17:42
Omeros Corporation (NASDAQ: OMER) today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery.
ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV PDF Print E-mail
Tuesday, 11 October 2011 17:40
ViiV Healthcare announces the start of the Phase III MODERN Study [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen], also known as A4001095, comparing its CCR5-inhibitor, Celsentri/Selzentry® (maraviroc), to emtricitabine/tenofovir (Truvada®), both in combination with darunavir/ritonavir.
Medtronic Announces Results from TTOP-AF Trial Demonstrating Clinical Benefits of Its Phased RF Ablation System in Treating Persistent Atrial Fibrillation PDF Print E-mail
Monday, 10 October 2011 05:30

Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical trial, the first randomized study comparing ablation therapy with the Medtronic Phased RF Ablation System ablation system to traditional medical management (antiarrhythmic drugs and direct current cardioversion) in 210 patients with persistent or long-standing persistent atrial fibrillation (AF).

Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate AndDisability Progression PDF Print E-mail
Saturday, 08 October 2011 17:46
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).
Puma Acquires Global Rights to Pfizer’s Phase III Breast Cancer Drug Neratinib PDF Print E-mail
Friday, 07 October 2011 01:40

Newly established Puma Biotechnology acquired global development and commercialization rights to Pfizer’s Phase III-stage anticancer drug neratinib.

Unigene and Nordic Bioscience Combine Industry Leading Capabilities to Advance Unigene’s Proprietary Peptides through Phase 2 Proof-of-Concept for the Treatment of Type 2 Diabetes, Osteoarthritis and Osteoporosis PDF Print E-mail
Friday, 07 October 2011 01:28

Unigene Laboratories, Inc. (OTCBB: UGNE) and Nordic Bioscience today announced their decision to establish a Joint Development Vehicle (JDV) to progress up to three of Unigene’s internally developed, proprietary calcitonin analogs through Phase 2 proof-of-concept in humans for the treatment of Type 2 diabetes, osteoarthritis and osteoporosis. Unigene and Nordic will each own 50% of the resulting JDV.

Halozyme Begins Randomized, Controlled Clinical Trial With PEGPH20 In Patients With Advanced Pancreatic Cancer PDF Print E-mail
Thursday, 06 October 2011 04:35
Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of patient dosing in a Phase 2 clinical trial with pegylated rHuPH20 (PEGPH20) in patients with stage IV previously untreated pancreatic cancer.
Boston Scientific Begins Clinical Trial Enrollment For OMEGA™ Platinum Chromium Stent System PDF Print E-mail
Thursday, 06 October 2011 04:31
Boston Scientific Corporation (NYSE: BSX) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and effectiveness of the Company's OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System in treating patients with a single coronary artery lesion.
Forest and Gedeon Richter Report Positive Phase III Data for Antipsychotic PDF Print E-mail
Wednesday, 05 October 2011 06:38

Forest Labs and Gedeon Richter reported positive topline data from a Phase III clinical study evaluating the antipsychotic candidate cariprazine (RGH-188) in patients with bipolar 1 disorder-associated acute mania.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 4 of 122